Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica.
Mult Scler
; 28(7): 1155-1159, 2022 06.
Article
em En
| MEDLINE
| ID: mdl-34931885
ABSTRACT
INTRODUCTION:
Recent studies suggested that anti-CD20 and fingolimod may be associated with lower anti-spike protein-based immunoglobulin-G response following COVID-19 vaccination. We evaluated if COVID-19 occurred despite vaccination among patients with multiple sclerosis (MS) and neuromyelitis optica (NMO), using the COVISEP registry. CASE SERIES We report 18 cases of COVID-19 after two doses of BNT162b2-vaccination, 13 of which treated with anti-CD20 and four with fingolimod. COVID-19 severity was mild.DISCUSSION:
These results reinforce the recommendation for a third COVID-19 vaccine dose among anti-CD20 treated patients and stress the need for a prospective clinical and biological study on COVID-19 vaccine efficacy among MS and NMO patients.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neuromielite Óptica
/
COVID-19
/
Vacina BNT162
/
Esclerose Múltipla
Tipo de estudo:
Diagnostic_studies
/
Guideline
Limite:
Humans
Idioma:
En
Revista:
Mult Scler
Ano de publicação:
2022
Tipo de documento:
Article